NASDAQ
Clinuvel Pharmaceuticals Limited (CLVLY) has a price/fcf ratio of 12.68x as of Tuesday, May 26, 2026. This represents a 65.84% decrease compared to its 12-month average of 37.12x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.
No price data available for this timeframe.